3 papers
stat.ME2024
"6 choose 4": A framework to understand and facilitate discussion of strategies for overall survival safety monitoring
Godwin Yung, Kaspar Rufibach, Marcel Wolbers +2
Advances in anticancer therapies have significantly contributed to declining death rates in certain disease and clinical settings. However, they have also made it difficult to powe…
stat.ME2024
Balancing events, not patients, maximizes power of the logrank test: and other insights on unequal randomization in survival trials
Godwin Yung, Kaspar Rufibach, Marcel Wolbers +2
We revisit the question of what randomization ratio (RR) maximizes power of the logrank test in event-driven survival trials under proportional hazards (PH). By comparing three app…
stat.AP2023
Considerations for Master Protocols Using External Controls
Jie Chen, Xiaoyun, Li +7
There has been an increasing use of master protocols in oncology clinical trials because of its efficiency and flexibility to accelerate cancer drug development. Depending on the s…